Peptide comparison
Retatrutide vs Survodutide
Retatrutide and Survodutide are both research peptides. This side-by-side compares their mechanism, typical research dosing, half-life, routes and safety so you can see how they differ. For research use only.
Reviewed by the Helica Labs research team · Last updated August 5, 2026
| Retatrutide | Survodutide | |
|---|---|---|
| Category | Metabolic | Metabolic |
| Overview | Investigational once-weekly triple agonist (GIP/GLP-1/glucagon) by Eli Lilly; phase 2 data show large weight loss. Not approved. | Investigational once-weekly glucagon/GLP-1 receptor dual agonist (BI 456906) from Boehringer Ingelheim/Zealand Pharma; phase 2 obesity and MASH data. Not approved. |
| How it works | Retatrutide is a single synthetic peptide that agonizes three incretin/metabolic receptors: GIP, GLP-1, and glucagon. GLP-1 and GIP agonism enhance glucose-dependent insulin secretion and promote satiety/slowed gastric emptying (reducing food intake), while glucagon-receptor agonism is proposed to increase energy expenditure and hepatic fat mobilization. A C20 fatty-diacid moiety promotes reversible binding to serum albumin, creating a depot effect that extends the half-life and supports once-weekly dosing. The combined appetite-suppression plus energy-expenditure mechanism is the leading hypothesis for its observed weight-loss magnitude, though the relative contribution of each receptor in humans is not fully resolved. | Survodutide is a single synthetic peptide engineered to activate two receptors involved in metabolic regulation: the glucagon receptor and the GLP-1 receptor. GLP-1 receptor agonism promotes satiety, slows gastric emptying, reduces food intake, and enhances glucose-dependent insulin secretion. Glucagon receptor agonism is proposed to raise energy expenditure and promote hepatic lipid metabolism, which may contribute both to weight loss and to the reductions in liver fat seen in MASH studies. The molecule is designed for once-weekly subcutaneous administration. The relative contribution of each receptor to the clinical effects in humans, and the optimal balance of the two activities, remain active questions under investigation. |
| Half-life | ~6 days (supports once-weekly dosing; steady state in ~4-5 weeks) | Survodutide is dosed once weekly by subcutaneous injection in clinical trials, consistent with a long-acting pharmacokinetic profile. A precise human elimination half-life is not prominently published; dosing is titrated gradually to steady state over several weeks. |
| Dosing reference | In Eli Lilly trials, retatrutide is given as a once-weekly subcutaneous injection with stepwise dose escalation to limit GI side effects. The phase 2 obesity trial used maintenance doses of 1, 4, 8, and 12 mg weekly, titrated upward over the first ~12-16 weeks (e.g., starting around 2-4 mg and increasing every 2-4 weeks). The largest weight loss occurred at 8-12 mg. These are investigational protocols; retatrutide has no approved label or established clinical dosing for general use. | In Boehringer Ingelheim trials, survodutide is given as a once-weekly subcutaneous injection with stepwise dose escalation to limit gastrointestinal side effects. The phase 2 obesity trial evaluated maintenance doses up to 4.8 mg weekly, and the phase 2 MASH trial used doses of 2.4, 4.8, and 6.0 mg weekly, each reached through a gradual titration schedule. These are investigational protocols; survodutide has no approved label or established clinical dosing for general use. |
| Routes | subcutaneous | subcutaneous |
| Safety & side effects | The most common adverse events in trials are gastrointestinal - nausea, vomiting, diarrhea, and constipation - which are dose-dependent, mostly mild-to-moderate, and concentrated during dose escalation; a lower starting dose and slower titration reduce them. Dose-dependent increases in heart rate (roughly 5-10 bpm) have been observed. Trial discontinuations due to adverse events ranged from about 6-16% across retatrutide arms. Through 48 weeks no hepatotoxicity signal was reported in the MASLD substudy, and no ketoacidosis occurred despite mild increases in ketone markers. As a glucagon-receptor agonist, blood-glucose effects warrant monitoring, particularly with concurrent diabetes medication. Long-term safety, cardiovascular outcomes, and effects of unregulated research-grade product are unknown. Class cautions for incretin agonists include pancreatitis, gallbladder issues, and a theoretical thyroid C-cell tumor signal seen in rodents. Not for use in pregnancy. Research-use-only; not approved for human consumption. | In phase 2 trials, the most common adverse events were gastrointestinal - nausea, vomiting, diarrhoea, and constipation - which were dose-dependent, mostly mild-to-moderate, and concentrated during dose escalation; slower titration reduces them. As with other incretin-based agents, the tolerability profile was broadly similar to GLP-1 receptor agonists. As a glucagon-receptor agonist, effects on blood glucose and heart rate warrant monitoring, and the full long-term safety profile will not be established until phase 3 data are complete and regulatory review is conducted. Long-term safety, cardiovascular outcomes, and the effects of unregulated research-grade material are unknown. Not for use in pregnancy. Research-use-only; not approved for human consumption. This information is for research reference only and is not medical advice. |
For research use only. Not for human consumption. Always verify against current literature.
Frequently asked questions
- What is the difference between Retatrutide and Survodutide?
- Retatrutide is categorised as a Metabolic research peptide, while Survodutide is categorised as Metabolic. This page sets their mechanism, research dosing, half-life and routes side by side so you can compare them. Both are supplied strictly for laboratory research use only.
- What are the half-lives of Retatrutide and Survodutide?
- The reported half-life of Retatrutide is ~6 days (supports once-weekly dosing; steady state in ~4-5 weeks), while Survodutide is Survodutide is dosed once weekly by subcutaneous injection in clinical trials, consistent with a long-acting pharmacokinetic profile. A precise human elimination half-life is not prominently published; dosing is titrated gradually to steady state over several weeks.. These figures are drawn from the research literature and are provided for reference only, not as dosing guidance.
- How are Retatrutide and Survodutide administered in research?
- In the literature, Retatrutide is studied via subcutaneous, while Survodutide is studied via subcutaneous. This is reference information about the compounds for laboratory research only — not directions for use.
- Can Retatrutide or Survodutide be used in humans?
- No. Both Retatrutide and Survodutide are sold strictly as research chemicals for laboratory research use only. They are not medicines, are not for human or veterinary consumption, and nothing on this page is medical or dosing advice.